A5012638755- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Multiple and Secondary Primary Cancers
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- Immunotherapy and Immune Responses
- Ovarian cancer diagnosis and treatment
- Galectins and Cancer Biology
- Vascular Malformations and Hemangiomas
- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Glycosylation and Glycoproteins Research
- Calcium signaling and nucleotide metabolism
- Histiocytic Disorders and Treatments
- Genomic variations and chromosomal abnormalities
University of Amsterdam
2010-2025
Amsterdam University Medical Centers
2018-2025
Amsterdam UMC Location University of Amsterdam
2012-2023
Centre for Research and Technology Hellas
2023
Cancer Center Amsterdam
2019-2022
Lymphoma Research Foundation
2019-2021
Hovon
2018
OLVG
2005
Abstract Morbidity and mortality due to immunosuppression remain among the foremost clinical challenges in chronic lymphocytic leukemia (CLL). Although is considered originate within lymph node (LN) microenvironment, alterations T natural killer (NK) cells have almost exclusively been studied peripheral blood (PB). Whereas chemoimmunotherapy further deteriorates immune function, novel targeted agents like B-cell lymphoma 2 inhibitor venetoclax potentially spare nonmalignant lymphocytes;...
Abstract Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due age, disease, and treatment-related immunosuppression. We aimed assess risk factors of outcome elucidate the impact CLL-directed treatments on course COVID-19. conducted a retrospective, international study, collectively including 941 patients CLL confirmed Data from beginning pandemic until March 16, 2021, were collected 91 centers. The case fatality rate (CFR),...
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP improve the mCR rate. In Phase I dose-escalation part 12 patients, we showed that BV-DHAP is feasible. This II study included 55 R/R cHL patients (23 primary refractory). Treatment consisted of three...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. analysis of Early positron emission tomography (ePET) Response–Adapted Treatment localized Hodgkin Lymphoma H10...
Summary Background Invasive fungal diseases (IFD) are life‐threatening infections most commonly diagnosed in acute leukaemia patients with prolonged neutropenia and uncommonly lymphoproliferative diseases. Objectives Following the initial report of aspergillosis shortly after beginning ibrutinib for chronic lymphocytic leukaemia, a survey was developed to seek additional cases IFD during treatment. Methods Local international physicians groups were approached relevant cases. Patients...
In patients with chronic lymphocytic leukemia (CLL), numbers of CD8 + CD45RA +/- CD27- effector T cells are expanded. We investigated whether this expansion is also present in other B cell malignancies and the possible mechanism underlying these changes. Whereas an increase total CD4+and CD8+ was found only CLL, CD4+ were significantly increased both CLL indolent lymphoma, but not aggressive lymphoma myeloma. Interestingly, PD-1 expression decreased on inversely correlated numbers,...
Background Bispecific antibodies are promising new therapeutics in B cell malignancies. Whether they lead to potent T activation despite described dysfunction chronic lymphocytic leukemia (CLL), and able effectively target high-risk or venetoclax-resistant samples, is currently unknown. Methods CD19 + lines primary (high-risk) CLL were cocultured vitro with healthy donor (HD) CLL-derived cells the presence of a CD3xCD19 dual affinity retargeting molecule (CD3xCD19 DART). Cell cytotoxicity,...